Search results
Showing 31 to 45 of 147 results for sclerosis
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)
Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)
Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.
Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease. This involves implanting electrodes into the diaphragm to make it contract. This gradually strengthens the diaphragm and may eventually help the person to breathe without a ventilator.
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)
Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]
In development Reference number: GID-TA11333 Expected publication date: TBC
Natalizumab for treating rapidly evolving severe relapsing–remitting multiple sclerosis (TA127)
Evidence-based recommendations on natalizumab (Tysabri) for treating rapidly evolving severe relapsing–remitting multiple sclerosis in adults.
Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis (HTG558)
Evidence-based recommendations on pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis in adults. This involves spraying the inside of the peritoneal cavity with chemotherapy.
View recommendations for HTG558Show all sections
Topic prioritisation
Masitinib for treating amyotrophic lateral sclerosis [ID967]
Discontinued Reference number: GID-TA10157
Tolebrutinib for treating primary progressive multiple sclerosis [TSID12166]
Topic prioritisation
Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)
Evidence-based recommendations on cladribine (Mavenclad) for treating active relapsing forms of multiple sclerosis in adults.
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
Discontinued Reference number: GID-TA10427